Swiss Biotech Stock News

Implenia (SWX:IMPN) has secured a contract exceeding €200 million to plan and build the new Münster police headquarters in Germany, a long-dated project with completion targeted for October 2029. See our latest analysis for Implenia. The contract news arrives after a mixed period for the stock, with the share price at CHF66.8 and a year-to-date share price return showing a decline of 15.44%, but a 1-year total shareholder return of 56.24%, suggesting that long-term momentum remains stronger...

If you are wondering whether Alcon's current share price still reflects good value or if the market has already priced in the story, this article walks through the key numbers so you can judge that for yourself. Alcon shares last closed at US$63.90, with returns of 3.7% over the past week, 6.7% over the last 30 days and 0.6% year to date, while the 1 year return stands at a 14.9% decline. Recent headlines around Alcon have focused on its position in eye care and medical equipment, along with...

Last week, SHL Telemedicine Ltd. ( VTX:SHLTN ) insiders, who had purchased shares in the previous 12 months were...

Novartis (SWX:NOVN) CEO Vas Narasimhan has joined the board of AI company Anthropic, marking the first time a major pharmaceutical chief executive has taken a board role at a leading artificial intelligence startup. Novartis is expanding global health and community outreach programs, targeting improved cancer and cardiovascular disease outcomes in over 30 countries by 2030. The company is also advancing late-stage therapies for myasthenia gravis, adding another area of focus to its...

Helvetia Baloise Holding (SWX:HBAN) has drawn fresh attention after reporting full year 2025 earnings and confirming an annual dividend of CHF 7.70 per share, scheduled for payment on May 29, 2026. See our latest analysis for Helvetia Baloise Holding. The 11.09% 30 day share price return, together with a 27.50% 1 year total shareholder return and a latest share price of CHF 222.40, indicates that momentum has been building around the recent earnings and dividend announcement. If these...

AI driven beauty launch puts Givaudan (SWX:GIVN) in focus Givaudan Active Beauty’s partnership with Haut.AI to showcase AI powered ingredient simulations at in cosmetics Global 2026 is drawing fresh attention to how the business connects scientific claims with consumer facing experiences. See our latest analysis for Givaudan. At a share price of CHF2,964.0, Givaudan has seen short term momentum pick up, with a 1 month share price return of 6.66% and 7 day gain of 5.56%. However, the 1 year...

Nestlé (SWX:NESN) is under scrutiny after the Teamsters union accused the company of anti union activity in several US facilities, raising fresh questions about its labor practices and broader corporate responsibility. See our latest analysis for Nestlé. Recent news around labor disputes and a possible exit from parts of the ice cream business comes as Nestlé’s share price edges higher, with a 90 day share price return of 5.02% but a 3 year total shareholder return decline of 25.43%,...

Investors in Burkhalter Holding AG ( VTX:BRKN ) had a good week, as its shares rose 7.9% to close at CHF184 following...

Wondering whether ABB at CHF 72.44 is priced for perfection or still offers value? This article walks you through what the current market price may be implying. The stock has posted returns of 2.3% over 7 days, 8.8% over 30 days, 18.3% year to date and 74.2% over 1 year, with a 3 year return of 142.6% and 5 year return of 185.3% that many investors will be weighing against the current valuation. Recent attention on ABB has centered on how its share price performance and business profile fit...

If you are wondering whether Amrize, at a last close of CHF45.16, still offers value or if the easy gains are gone, this article walks you through what the current price might really imply. The stock has recently posted returns of 0.9% over 7 days, 2.3% over 30 days and 1.5% year to date. This naturally raises questions about how much of its potential is already reflected in the price. Recent coverage of Amrize has focused on providing investors with evergreen context around the company and...

It looks like UBS Group AG ( VTX:UBSG ) is about to go ex-dividend in the next three days. The ex-dividend date is...

It looks like Flughafen Zürich AG ( VTX:FHZN ) is about to go ex-dividend in the next three days. The ex-dividend date...

Recent share performance and business scale Novartis (SWX:NOVN) has recently seen a 0.8% decline over the past day and a 3.9% decline over the past week, with the share price closing at CHF 117.42. Over the past month the stock shows a 3.6% decline, while the past 3 months reflect a 1.6% total return and the past year a 33.5% total return. Measured over 5 years, the total return stands at 83.6%. The company reports annual revenue of $56.7b and net income of $14.0b, with both revenue and net...

Barry Callebaut (SWX:BARN) has released its H1 2026 scorecard with Total Revenue of CHF 7.5b and Basic EPS of CHF 28.03 in the second half of 2025, alongside CHF 7.3b of revenue and EPS of CHF 5.85 in the first half. Trailing twelve month EPS stands at CHF 33.90 on CHF 14.8b of revenue, framing the latest read on profitability. The company’s Total Revenue has increased from CHF 5.7b and EPS of CHF 20.40 in H2 2024 to the current H2 2025 levels, drawing investor attention to how slim margins...

Why Temenos Is On Investors’ Radar Today Temenos (SWX:TEMN) is drawing attention after a recent share price move, with the stock up 3% over the past day and about 10.5% over the past week, prompting a closer look at fundamentals. See our latest analysis for Temenos. That short burst of share price momentum, with a 10.53% 7 day share price return and the stock now at CHF77.7, sits against a year to date share price return of a 4.66% decline and a 1 year total shareholder return of 25.64%. This...

If you are wondering whether Roche Holding's current share price still offers value, the key is to look past the headline moves and focus on what different valuation methods are really saying. The stock trades at CHF313.50 after a 1% decline over the last week and 3.2% over the past month, while the 1 year return sits at 26.4% and the 3 and 5 year returns are 25.2% and 18.3% respectively. Recent attention on Roche often centers on its position as a major Swiss pharmaceuticals and biotech...

As European markets rally, buoyed by a U.S.-Iran ceasefire and positive investor sentiment, the pan-European STOXX Europe 600 Index has seen a notable increase of 3.05%. In this environment of cautious optimism, dividend stocks can offer an attractive proposition for investors seeking steady income streams amidst market fluctuations.

Guidance confirmation puts Sika (SWX:SIKA) back in focus Sika (SWX:SIKA) has drawn fresh attention after management reiterated 2026 earnings guidance, signaling an expectation for 1% to 4% sales growth in local currencies and a continued aim to outperform its reference market, including bolt-on acquisitions. See our latest analysis for Sika. The guidance confirmation comes after a sharp short term rebound, with a 7 day share price return of 9.06% and a 30 day share price return of 11.14%,...

Switzerland’s Federal Criminal Court has cleared UBS Group of liability in the Mozambique tuna bond money laundering case. The decision relates to alleged misconduct tied to Credit Suisse, which UBS acquired in 2023. The ruling removes a major legal overhang linked to pre acquisition Credit Suisse activities for UBS Group. For investors tracking SWX:UBSG, this court decision lands at a time when the stock is trading at CHF33.48 and has shown strong longer term share price gains, with a...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...

Nestlé S.A. ( VTX:NESN ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business...

Cosmo Pharmaceuticals N.V. reported that shareholders at its recent Ordinary AGM approved all proposals, including a €2.10 per share dividend, with the ex-dividend date set for 24 April 2026 and payment on 11 May 2026. This broad shareholder backing for both governance items and a cash distribution highlights confidence in the company’s capital allocation approach and cash-generating capacity. We’ll now examine how this newly approved €2.10 dividend and strong shareholder support feed into...

R&S Group Holding AG recently reported its full-year 2025 results, with sales rising to CHF 414.84 million and net income reaching CHF 58.1 million, both higher than the prior year. The improvement in basic earnings per share from continuing operations to CHF 1.56 highlights enhanced profitability on a per-share basis alongside the company’s broader growth. With this earnings-driven backdrop and stronger per-share profitability, we will explore how these results shape R&S Group Holding’s...

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...